Description:
This is an open-label Phase 2 study which will evaluate the efficacy and safety of belzutifan
in combination with cabozantinib in participants with advanced ccRCC. Belzutifan and
cabozantinib will be administered orally once daily.
Title
- Brief Title: A Trial of Belzutifan (PT2977, MK-6482) in Combination With Cabozantinib in Patients With Clear Cell Renal Cell Carcinoma (ccRCC) (MK-6482-003)
- Official Title: A Phase 2 Trial of PT2977 in Combination With Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma
Clinical Trial IDs
- ORG STUDY ID:
6482-003
- SECONDARY ID:
PT2977-201
- SECONDARY ID:
MK-6482-003
- NCT ID:
NCT03634540
Conditions
- Renal Cell Carcinoma (RCC)
- Clear Cell Renal Cell Carcinoma (ccRCC)
- Kidney Cancer
- Renal Cancer
- Renal Cell Carcinoma
- Renal Cell Cancer Metastatic
- Renal Cell Carcinoma Recurrent
- Renal Cell Cancer, Recurrent
- Kidney
Interventions
Drug | Synonyms | Arms |
---|
Belzutifan | PT2977, MK-6482, WELIREG | Belzutifan + Cabozantinib: Prior Immunotherapy (Cohort 2) |
Cabozantinib | CABOMETYX® | Belzutifan + Cabozantinib: Prior Immunotherapy (Cohort 2) |
Purpose
This is an open-label Phase 2 study which will evaluate the efficacy and safety of belzutifan
in combination with cabozantinib in participants with advanced ccRCC. Belzutifan and
cabozantinib will be administered orally once daily.
Trial Arms
Name | Type | Description | Interventions |
---|
Belzutifan + Cabozantinib: Treatment Naïve (Cohort 1) | Experimental | Naïve participants will receive 120 mg belzutifan and 60 mg cabozantinib orally once daily (QD) at the same time. | |
Belzutifan + Cabozantinib: Prior Immunotherapy (Cohort 2) | Experimental | Participants who have received prior immunotherapy will receive 120 mg belzutifan and 60 mg cabozantinib orally QD at the same time. | |
Eligibility Criteria
Inclusion Criteria:
- Has locally advanced or metastatic RCC with predominantly clear cell subtype
- Has at least one measurable lesion as defined by RECIST version 1.1
- Eastern Cooperative Oncology Group (ECOG) performance status of 0-1
- Has adequate organ function defined as follows:
- Absolute neutrophil count ≥ 1,000/µL, hemoglobin level ≥ 10 g/dL and platelet
count ≥ 100,000/µL without transfusion or growth factor support within 2 weeks
prior to obtaining the hematology values at screening;
- Serum creatinine level ≤ 2.0 × upper limit of normal (ULN)
- Transaminase levels (AST/ALT) ≤ 3.0 × upper limit of normal (ULN); total
bilirubin (TBILI) ≤ 1.5 mg/dL in the absence of Gilbert's disease *Cohort 1:
Participants must not have received prior systemic therapy for advanced or
metastatic ccRCC
- Cohort 2: Participants must have received prior immunotherapy and no more than two
prior treatments for advanced or metastatic ccRCC
Exclusion Criteria:
- Has received prior treatment with belzutifan or other HIF2α inhibitors
- Has received prior treatment with cabozantinib
- Has had radiation therapy for bone metastases within two weeks of starting study drug
- Has a history of untreated brain metastases or history of leptomeningeal disease or
spinal cord compression
- Has failed to recover from the reversible effects of prior anticancer therapy
- Has uncontrolled or poorly controlled hypertension
- Is receiving anticoagulant therapy
- Has had any major cardiovascular event within 6 months prior to study drug
administration
- Has any other clinically significant cardiac, respiratory, or other medical or
psychiatric condition that might interfere with participation in the trial or
interfere with the interpretation of trial results
- Has had major surgery within 3 months before first study drug administration
- Has an active infection requiring systemic treatment
- Is participating in another therapeutic clinical trial
Maximum Eligible Age: | N/A |
Minimum Eligible Age: | 18 Years |
Eligible Gender: | All |
Healthy Volunteers: | No |
Primary Outcome Measures
Measure: | Overall Response Rate (ORR) |
Time Frame: | Up to approximately 2 years |
Safety Issue: | |
Description: | ORR is defined as the percentage of participants with a best confirmed response of Complete Response (CR: disappearance of all target lesions) or Partial Response (PR: ≥30% decrease in the sum of diameters of target lesions) as determined by the investigator using Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1). |
Secondary Outcome Measures
Measure: | Progression Free Survival (PFS) |
Time Frame: | Up to approximately 2 years |
Safety Issue: | |
Description: | PFS is defined as the interval from the start of study treatment until the earlier of the first documentation of disease progression determined by RECIST 1.1 or death from any cause. |
Measure: | Duration of Response (DOR) |
Time Frame: | Up to approximately 2 years |
Safety Issue: | |
Description: | DOR is defined as the interval from the first documentation of response, as determined by RECIST 1.1, to the earlier of the first documentation of disease progression or death from any cause, and calculated for participants with a best confirmed response of CR (disappearance of all target lesions) or PR (≥30% decrease in the sum of diameters of target lesions). |
Measure: | Time to Response (TTR) |
Time Frame: | Up to approximately 2 years |
Safety Issue: | |
Description: | TTR is defined as the interval from the start of study treatment to the first documentation of a response, as determined by RECIST 1.1, and calculated for participants with a best confirmed response of CR or PR. |
Measure: | Overall Survival (OS) |
Time Frame: | Up to approximately 2 years |
Safety Issue: | |
Description: | OS is defined as the interval from the start of treatment to the death of the participant from any cause. |
Measure: | Number of participants experiencing an Adverse Event (AE) |
Time Frame: | Up to approximately 2 years |
Safety Issue: | |
Description: | An AE is defined as any untoward medical occurrence in a participant regardless of its causal relationship to study treatment. An AE can be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of the study drug, whether or not it is considered to be study drug related. Included in this definition are any newly occurring events and any previous condition that has increased in severity or frequency since the administration of study drug. |
Measure: | Number of participants discontinuing study treatment due to an Adverse Event (AE) |
Time Frame: | Up to approximately 2 years |
Safety Issue: | |
Description: | An AE is defined as any untoward medical occurrence in a participant regardless of its causal relationship to study treatment. An AE can be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of the study drug, whether or not it is considered to be study drug related. Included in this definition are any newly occurring events and any previous condition that has increased in severity or frequency since the administration of study drug. |
Measure: | Belzutifan Plasma Concentration |
Time Frame: | Weeks 1 and 4: pre-dose, 2 and 6 hours post-dose |
Safety Issue: | |
Description: | Blood samples for the determination of belzutifan concentration will be collected at pre-specified timepoints before and after treatment administration. |
Measure: | Belzutifan Metabolite Plasma Concentration |
Time Frame: | Weeks 1 and 4: pre-dose, 2 and 6 hours post-dose |
Safety Issue: | |
Description: | Blood samples for the determination of belzutifan metabolite concentration will be collected at pre-specified timepoints before and after treatment administration. |
Measure: | Cabozantinib Plasma Concentration |
Time Frame: | Weeks 1 and 4: pre-dose, 2 and 6 hours post-dose |
Safety Issue: | |
Description: | Blood samples for the determination of cabozantinib concentration will be collected at pre-specified timepoints before and after treatment administration. |
Details
Phase: | Phase 2 |
Primary Purpose: | Interventional |
Overall Status: | Recruiting |
Lead Sponsor: | Peloton Therapeutics, Inc. |
Trial Keywords
- hypoxia-inducible factor (HIF)
- hypoxia-inducible factor 2 alpha (HIF-2α, HIF-2 alpha)
Last Updated
September 1, 2021